An exploratory study regarding the use of the biomarker DAT for image diagnosis of clear cell renal cell carcinoma.

Trial Profile

An exploratory study regarding the use of the biomarker DAT for image diagnosis of clear cell renal cell carcinoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Ioflupane 123I (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Diagnostic use
  • Acronyms RCCSCAN
  • Most Recent Events

    • 11 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 06 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top